AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04549259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-Based Social Support
Description: This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 8 consecutive weeks. The calls will last approximately 90 minutes and will include 5-8 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Therapists will facilitate mutual support among group members, encourage greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy (Heckman et al., 2013).
Study NCT04549259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Stigma Reduction
Description: This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 6 consecutive weeks. The calls will last approximately 60-90 minutes and will include 5-8 individuals per group. This intervention is grounded in minority stress theory and will use cognitive-behavioral strategies to help empower participants to cope with stressful and stigmatizing experiences. Intervention components may include minimizing self-stigmatizing attitudes, reducing engulfment, developing a sense of future and hope, and developing and pursuing meaningful life goals. This intervention is an adaptation of Ending Self Stigma (Lucksted et al., 2011).
Study NCT04549259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-Based Case Management (SBCM)
Description: The investigators have adapted an individually-tailored strengths-based case management (SBCM) intervention to help address the multiple structural barriers faced by rural older PLH. The adapted intervention, delivered by trained research staff, will include two 60-minute telephone-based SBCM counseling sessions with shorter follow-up phone calls to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
Study NCT04549259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Technology Detailing
Description: Participants will be called by a technology-fluent study staff member, who will assess the current state of their technology literacy, access, and use. Detailing will focus on advancing the participant along the technology use cascade (using the internet, possessing a device and service to access internet at home, using the internet to access their electronic health record and pharmacy services, seeking HIV-related information, and finding social support). Each participant will be provided with personalized assistance based on their local and personal circumstances. Because of the individualized advice provided, there will be a range of contacts between 1 and 5, at customized intervals. Detailing protocols include the option of providing the participant with a tablet including cellular service (for 3 months) when in-home internet service is not available or is cost prohibitive.
Study NCT04576806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body temperature
Description: Warming of administered fluid bolus
Study NCT04576806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid bolus
Description: Administration of fluid bolus of crystalloid of 500ml over 15 minutes
Study NCT04576806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid bolus
Description: Administration of fluid bolus of crystalloid of 500ml over 15 minutes
Study NCT04576806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room temperature
Description: Cooling of administered fluid bolus
Study NCT04965610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoxygenation with High Flow Nasal Cannula
Description: Preoxygenation for 5 minutes via High Flow Nasal Cannula. After induction of anaesthesia apnoeic oxygenation with HFNC
Study NCT04965610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation via face mask
Description: Preoxygenation for 5 minutes via face mask. After induction of anaesthesia apnoeic oxygenation with tight fitting face mask
Study NCT04047212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy for oral cancer
Description: surgical biopsy is to be taken for diagnosis of oral cancer or premalignant lesions
Study NCT04047212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: periodontal examination
Description: Periodontal clinical examination to all by periodontal charting
Study NCT04931628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvianolic Acid
Description: salvianolic acid, injection, 100mg+0.9%NaCl 250ml, qd, 14 days
Study NCT04931628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: 0.9% NaCl
Study NCT06742749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal level
Description: For the proximal level of psoas tenotomy at the pelvic brim, the hip was slightly flexed to relax the iliopsoas muscle; the iliacus muscle fibers were retracted anteriorly until the deeply seated posteromedially psoas tendon was isolated and transected
Study NCT06742749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal level
Description: For the distal level of iliopsoas tenotomy just above the lesser trochanter, the thigh was put in the position of FABER (flexion, abduction, and external rotation). A curved right-angle hemostatic clamp was used to retract and bring the iliopsoas tendon into the field. Then, the tendinous fibers were transected.
Study NCT06752460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EF192B
Description: EF192B will be applied after the tape strriping procedure and will be reapplied after 12 hours.
Study NCT06752044 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-based peptide vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
Study NCT06752044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
Study NCT06752044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-based peptide vaccine
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study NCT06752408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib
Description: Aumolertinib will be administered orally at a dose of 110 mg per time, Q.D.
Study NCT06752408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
Study NCT06754865 — intervention group
Intervention type: DRUG
Intervention: Xiyanping injection+ antibiotic
Description: Xiyanping injection+ antibiotic
Study NCT06754865 — intervention group
Intervention type: DRUG
Intervention: Antibiotic
Description: Antibiotic
Study NCT06754748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Description: 11 g caffeinated coffee made with 200 ml water was given to participants.
Study NCT06754748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Description: 11 g decaffeinated coffee made with 200 ml water was given to participants.
Study NCT06754748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 200 ml water was given to participants.
Study NCT06752330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Use of probiotics during oral hygiene at home
Description: The probiotic used in the study is Bifidobacterium Lactis HN019, distributed com-mercially in Italy by Curasept (Curasept Prevent®, Curasept S.p.A., Saronno, VA, Italy), with added Kluyveromyces Marxianus Fragilis B0399, colostrum and biotin. The probiotic was taken by patients following the manufacturer's directions via 2 chewable tablets daily, morning and evening, after normal daily oral hygiene, achieving daily average values of B. Lactis HN019 of 2\*107 CFU and Kluyveromyces marxianus fragilis B0399 of 2\*109 CFU.
Study NCT06752733 — intervention group
Intervention type: PROCEDURE
Intervention: electrical cardioversion
Description: synchronized electrical shocks to restore normal sinus rhythm in patients with atrial fibrillation, performed under sedation
Study NCT06756061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone + Jakavi(ruxolitinib)
Description: The experimental group will receive ruxolitinib 10 mg orally twice daily (BID) and prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease. (However, after the 48-week mark, participants in the ruxolitinib treatment group may continue to receive ruxolitinib for an additional maximum of 2 years, based on the investigator's judgment regarding the need for ongoing treatment. The total duration of ruxolitinib administration will not exceed 3 years.)
Study NCT06756061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: The control group will receive prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease.
Study NCT06752447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNF2007
Description: LNF2007，9 dose groups:0.2μg/kg、1μg/kg、5μg/kg、20μg/kg、60μg/kg、120μg/kg、240μg/kg、360μg/kg、540μg/kg（0.2\~5μg/kg for accelerated titration, and i3+3 ramp-up starting from 20μg/kg dose group），IV, infusion time 60min±10min, Q4W, until disease progression 、intolerable toxicity or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
Study NCT06752902 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care Arm
Description: standard care combined with personalised prevention
Study NCT06752902 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard care combined with personalised prevention
Description: standard care combined with personalised prevention
Study NCT06754410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: group A take tamsulosin once daily
Study NCT06754410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: give cetirizine once dailly
Study NCT06754410 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine + Tamsulosin
Description: both once daily
Study NCT06754410 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once dailly
Study NCT06753929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wireless wearable thermal anisotropy measurement device
Description: non-invasive device used for assessing CSF shunt flow via thermal anisotropy measurements in a routine outpatient clinic setting
Study NCT05787171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WE-MBVMS using suture Vicryl (Polyglactin 910; Johnson & Johnson International, USA);
Description: The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
Study NCT05787171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WE-MBVMS using suture PDS (polydioxanone; Johnson & Johnson International, USA)
Description: The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
Study NCT05787171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WE-MBVMS using suture Ethibond (polyester; Johnson & Johnson International, USA）
Description: The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
Study NCT04743453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg: Study drug will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
Study NCT04743453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
Study NCT05483192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral Dyglomera
Description: Measurement of body weight, waist circumference, hip circumference, waist to hip ratio, body mass index, body fat.~Blood draw and measurement of blood total Cholesterol, HDL-cholesterol, LDL-cholesterol), ALT, AST, Fasting Blood Glucose, CRP, adiponectin, and leptin.
Study NCT05483192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Dyglomera
Description: Measurement of body weight, waist circumference, hip circumference, waist to hip ratio, body mass index, body fat.~Blood draw and measurement of blood total Cholesterol, HDL-cholesterol, LDL-cholesterol), ALT, AST, Fasting Blood Glucose, CRP, adiponectin, and leptin.
Study NCT06195878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Therapy
Description: Continuous positive airway pressure (CPAP) therapy in the management of moderate-to-severe sleep-related breathing disorders (SRBDs)/sleep apnea.
Study NCT04607837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
Study NCT04607837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
Study NCT05267756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (kurki-application),VR glasses
Description: it is virtual reality immersive based-exercise game
Study NCT06754618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi
Description: Cuffs will be worn throughout the entire training session. Training session consist of lower intensity bicep curls. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
Study NCT06754618 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Delfi
Description: Cuffs will be worn throughout the entire training session. Training session consist of lower intensity bicep curls. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
Study NCT06754033 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Interventional group I
Description: Intervention Details: Participants in this arm will receive a Ganglion Impar Block, a minimally invasive injection aimed at blocking pain signals from the coccyx region (Ganglion Impar Block using Triamcinolone Acetate (40 mg) and Bupivacaine (0.25%) administered with a 22G Spinal Needle under Fluoroscopic Guidance). Participants in this arm will receive a Ganglion Impar Block, a minimally invasive procedure involving the administration of Triamcinolone Acetate (a corticosteroid) and Bupivacaine (a local anesthetic). This is intended to block pain signals originating from the coccyx region. The procedure will be conducted under fluoroscopic guidance to ensure precise delivery. The injection will be complemented by a structured physical therapy program, including heat therapy, ultrasound, posture training, core strengthening exercises, and mobility activities to improve pain relief and functional capacity.
Study NCT06754033 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Interventional group II
Description: Intervention Details: Participants in this arm will receive a Caudal Epidural Steroid Injection Caudal Epidural Steroid Injection using Triamcinolone Acetate (40 mg), Bupivacaine (0.25%), and Normal Saline (6 mL) administered with a 22G Spinal Needle under Fluoroscopic Guidance), designed to deliver anti-inflammatory medication directly to the epidural space, thereby reducing inflammation and pain. This will also be paired with a tailored physical therapy program, focusing on similar modalities as in Arm 1, including heat therapy, ultrasound, posture training, and strengthening exercises. The objective is to enhance pain relief and functional recovery in the context of coccydynia.
Study NCT06752954 — intervention group
Intervention type: DEVICE
Intervention: Viabahn endoprosthesis group
Description: Viabahn endoprosthesis group：Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
Study NCT06752954 — intervention group
Intervention type: DEVICE
Intervention: Drug-coated balloon group
Description: Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
Study NCT06752980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye mask
Description: The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
Study NCT06752980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Earplugs
Description: The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
Study NCT06752980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Mask and Earplugs
Description: The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
Study NCT06752551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Apprehension-based training
Description: This intervention is comprised of the 3 phases:~Static phase - Isometric (static) exercises performed in progressively greater shoulder apprehension (instability) provoking conditions Dynamic phase: Isotonic (dynamic) exercises using shoulder apprehension-provoking movement patterns at a gradually increasing pace of movement.~Neurocognitive phase: Dynamic phase exercises are continued at a high pace with the addition of cognitive tasks (distractions).~The intervention is guided by a physical therapist and includes up to 4 individual (one on one) sessions. In each session the physical therapist assesses exercise performance quality and when appropriate progresses exercise intensity and/or phase. Patients are expected to perform home exercises according to their phase of the program on a daily basis in between physical therapy sessions.
Study NCT06752551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Standard physical will be provided based on the assessment and judgment of the physical therapist. Intervention may include active exercises for increased shoulder mobility, muscle strength and neuromuscular control. Intervention may also include manual therapies such as massage, soft-tissue and joint mobilizations, dry needling, and electrophysiological modalities. No more than 4 individual sessions with a physical therapist will be provided over the course of treatment with some form of a home exercise program in between.
Study NCT06754631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Nebulization of Salbutamol
Description: Children received continuous nebulization of salbutamol at a concentration of 0.3 mg/kg/hour for 4 hours, with a minimum of 5 mg/hour and a maximum of 15 mg/hour administered via High Output Extended Aerosol Respiratory Therapy (HEART).